-
Alkermes Looks To Capitalize On Opioid Epidemic Through Aggressive Lobbying
Monday, June 12, 2017 - 12:00pm | 377Read More...The U.S. Food and Drug Administration's quest to address the growing opioid crisis is hurting many pharmaceutical companies, including Endo International plc - Ordinary Shares (NASDAQ: ENDP), presenting an opportunity for companies like Alkermes Plc (NASDAQ: ALKS), which makes treatments for opioid...
-
Big Biotech In The Earnings Spotlight
Tuesday, April 26, 2016 - 8:08am | 735Read More...The three largest biotechs are set to share their latest quarterly results this week. Wall Street analysts are looking for solid to strong growth from all three. However, expectations are lower for many other biotech and pharmaceutical companies reporting this week. The three largest public...
-
4 SMID-Cap Biotechs Barclays Just Confessed It Loves
Thursday, May 21, 2015 - 9:00am | 550Read More...In a new research note, Barclays analysts said that the run in biotech stocks is not over. In fact, the firm initiated coverage on four names, three of which it started with Overweight ratings. On that Overweight side, Barclays likes Alkermes Plc (NASDAQ: ALKS), Esperion Therapeutics Inc (...
-
Why Citigroup Placed An $85 Price Target On Shares Of Alkermes
Wednesday, January 14, 2015 - 3:37pm | 245Read More...Citigroups' Jonathan Eckard, Ph.D. continues to believe that Alkermes Plc (NASDAQ: ALKS) is a top name among biotech stocks and remains on the Citi U.S. Focus List. On Wednesday, Eckard increased his price target on Buy-rated Alkermes to $85 from a previous $72, reflecting the belief that...
-
Market Wrap For April 8: Markets Bounce Higher As Earnings Season Begins
Tuesday, April 8, 2014 - 4:54pm | 2569Read More...U.S. stocks rose as major indices finished the day just barely in the green as the Dow was up as much as 50 points and lower by 65 points before settling the day gaining 10 points. The Nasdaq bounced back sharply from its worst three-day performance since 2011 as investors went bargain hunting...
-
Jefferies Comments on Acquisition at Alkermes
Tuesday, August 2, 2011 - 7:07am | 130Read More...Jefferies has published a report on Alkermes (NASDAQ: ALKS) covering a recent acquisition by the biotechnology company. According to Jefferies, "Alkermes posted a strong quarter with impressive top-line growth. With the EDT transaction to close in September, investor focus will be on a successful...
-
Bank of America has published a report on Alkermes (NASDAQ: ALKS) after a drug court professionals conference.
Tuesday, July 26, 2011 - 7:56am | 149Read More...In the report, Bank of America wrote, "Funding is key to Vivitrol uptake in drug court setting We recently attended the annual National Association of Drug Court Professionals (NADCP) conference in Washington DC. The feedback from attendees indicated that the drug court setting could provide a...
-
Jefferies & Company Reports on Alkermes
Thursday, May 19, 2011 - 7:48am | 148Read More...In a report released today, Jefferies & Company commented on Alkermes (NASDAQ: ALKS). In the report, Jefferies was mixed in its assessment of the company. Jefferies writes, “Alkermes is making investments to build a long term, sustainably profitable company. The EDT acquisition diversifies the...
-
JP Morgan Raises PT On Alkermes To $21
Thursday, May 19, 2011 - 7:33am | 26Read More...JP Morgan has raised the price target on Alkermes (NASDAQ: ALKS) from $16 to $21 and maintains its Overweight rating.
-
Hapoalim Reiterates Buy on Alkermes (ALKS)
Friday, February 4, 2011 - 11:54am | 125Read More...Hapoalim is out with its report today on Alkermes (NASDAQ: ALKS), reiterating Buy and a $16 price target. In a note to clients, Hapoalim writes, "Last night, Alkermes reported fiscal 3Q11 earnings of ($0.12), which was $0.04 above our and the consensus estimate. Total revenues were $0.4 million...
-
Jefferies & Company Projects Alkermes Sales of $40M
Wednesday, October 13, 2010 - 8:42am | 90Read More...Vivitrol drug maker Alkermes, Inc. (NASDAQ: ALKS) announced last night that it received FDA approval for an expanded indication that includes "the prevention of relapse to opioid dependence," Jefferies & Company reports. “We are currently projecting CY11 sales of $40M,” Jefferies & Company...
-
PRX, ALKS, Initiated At Buy
Thursday, September 30, 2010 - 10:23am | 39Read More...UBS has initiated coverage for the following companies: Par Pharmaceutical Companies (NYSE: PRX) Buy, $35 price target Alkermes Inc. (NASDAQ: ALKS) Buy, $18 price target
